Skip to main navigation Skip to search Skip to main content

Phase 1/2 Open label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B ALL) and Minimal Residual Disease Positive (MRD+) B ALL

  • Fleming, Shaun (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)
  • Yeung, David (Chief Investigator (CI))
  • Kwan, John (Chief Investigator (CI))
  • Leahy, Michael (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date21/02/23 → 20/02/27

Keywords

  • Clinical trial
  • Haematology
  • B-ALL

Clinical Trial Phase

  • Phase I
  • Phase II